Two Sigma Investments, LP Aptinyx Inc. Transaction History

Two Sigma Investments, LP

  • $42.3 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.12 - $0.69 $11,159 - $64,165
-92,993 Reduced 53.38%
81,232 $9,000
Q4 2022

Feb 14, 2023
SELL
$0.23 - $0.34 $2,369 - $3,502
-10,300 Reduced 5.58%
174,225 $50,000
Q3 2022

Nov 14, 2022
SELL
$0.35 - $0.72 $15,036 - $30,932
-42,962 Reduced 18.89%
184,525 $68,000
Q2 2022

Aug 15, 2022
BUY
$0.38 - $2.58 $71,979 - $488,706
189,421 Added 497.61%
227,487 $127,000
Q1 2022

May 16, 2022
SELL
$2.27 - $3.62 $18,241 - $29,090
-8,036 Reduced 17.43%
38,066 $86,000
Q4 2021

Feb 14, 2022
BUY
$2.11 - $3.0 $51,066 - $72,606
24,202 Added 110.51%
46,102 $123,000
Q3 2021

Nov 15, 2021
SELL
$2.21 - $2.89 $68,952 - $90,168
-31,200 Reduced 58.76%
21,900 $51,000
Q2 2021

Aug 16, 2021
SELL
$2.39 - $3.5 $1.47 Million - $2.16 Million
-617,011 Reduced 92.08%
53,100 $150,000
Q1 2021

May 17, 2021
BUY
$2.86 - $4.33 $679,181 - $1.03 Million
237,476 Added 54.89%
670,111 $2.01 Million
Q4 2020

Feb 16, 2021
BUY
$2.93 - $4.3 $849,075 - $1.25 Million
289,787 Added 202.86%
432,635 $1.5 Million
Q3 2020

Nov 16, 2020
BUY
$3.05 - $4.99 $151,676 - $248,152
49,730 Added 53.41%
142,848 $483,000
Q2 2020

Aug 14, 2020
SELL
$1.99 - $4.4 $37,525 - $82,970
-18,857 Reduced 16.84%
93,118 $388,000
Q1 2020

May 15, 2020
SELL
$1.81 - $5.03 $15,216 - $42,287
-8,407 Reduced 6.98%
111,975 $242,000
Q4 2019

Feb 14, 2020
SELL
$2.84 - $4.25 $131,190 - $196,324
-46,194 Reduced 27.73%
120,382 $412,000
Q3 2019

Nov 14, 2019
SELL
$3.0 - $4.08 $120,456 - $163,820
-40,152 Reduced 19.42%
166,576 $581,000
Q2 2019

Aug 14, 2019
BUY
$2.95 - $4.38 $270,860 - $402,158
91,817 Added 79.9%
206,728 $690,000
Q1 2019

May 15, 2019
BUY
$3.99 - $19.33 $458,494 - $2.22 Million
114,911 New
114,911 $465,000

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email